Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Previously Treated EGFR-Mutant NSCLC
NCT02321540Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2015
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Mar 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02321540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321540.